Cargando…
The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model
BACKGROUND: The number of young patients with hepatocellular carcinoma (HCC) is increasing, but whether patients of different ages have a survival advantage is unclear. This study was conducted to investigate whether age differences in the Barcelona Clinic Liver Cancer (BCLC) classification system c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855543/ https://www.ncbi.nlm.nih.gov/pubmed/35180841 http://dx.doi.org/10.1186/s12885-022-09293-x |
_version_ | 1784653672309850112 |
---|---|
author | Yan, Huiwen Wang, Xinhui Liu, Xiaoli Wang, Peng Yu, Lihua Zhou, Dongdong Yang, Zhiyun |
author_facet | Yan, Huiwen Wang, Xinhui Liu, Xiaoli Wang, Peng Yu, Lihua Zhou, Dongdong Yang, Zhiyun |
author_sort | Yan, Huiwen |
collection | PubMed |
description | BACKGROUND: The number of young patients with hepatocellular carcinoma (HCC) is increasing, but whether patients of different ages have a survival advantage is unclear. This study was conducted to investigate whether age differences in the Barcelona Clinic Liver Cancer (BCLC) classification system contribute to the long-term survival outcomes of patients with HCC. METHODS: A total of 1602 patients with HCC admitted to the Beijing Ditan Hospital was included in this study. Patients were divided into younger (≤45 years) and older (> 45 years) groups. Factors determining overall survival and progression-free survival were analyzed using univariate and multivariate analyses with the Kaplan-Meier method and Cox proportional hazard regression model. We calculated the cumulative incidence function using the Fine-Gray model. The effect of mortality on age was also estimated using a restricted cubic spline. RESULTS: After matching, overall survival and progression-free survival were significantly better in younger patients than in older patients with BCLC stage 0-B (p = 0.015 and p = 0.017, respectively). In BCLC stage 0-B, all-cause mortality increased with age and increased rapidly around the age of 40 years (non-linear, p < 0.05). In BCLC stages 0-B, HCC-related and non-HCC-related deaths significantly differed between younger and older individuals (p = 0.0019). CONCLUSION: In stage BCLC 0-B, age affects the long-term prognosis of patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09293-x. |
format | Online Article Text |
id | pubmed-8855543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88555432022-02-23 The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model Yan, Huiwen Wang, Xinhui Liu, Xiaoli Wang, Peng Yu, Lihua Zhou, Dongdong Yang, Zhiyun BMC Cancer Research BACKGROUND: The number of young patients with hepatocellular carcinoma (HCC) is increasing, but whether patients of different ages have a survival advantage is unclear. This study was conducted to investigate whether age differences in the Barcelona Clinic Liver Cancer (BCLC) classification system contribute to the long-term survival outcomes of patients with HCC. METHODS: A total of 1602 patients with HCC admitted to the Beijing Ditan Hospital was included in this study. Patients were divided into younger (≤45 years) and older (> 45 years) groups. Factors determining overall survival and progression-free survival were analyzed using univariate and multivariate analyses with the Kaplan-Meier method and Cox proportional hazard regression model. We calculated the cumulative incidence function using the Fine-Gray model. The effect of mortality on age was also estimated using a restricted cubic spline. RESULTS: After matching, overall survival and progression-free survival were significantly better in younger patients than in older patients with BCLC stage 0-B (p = 0.015 and p = 0.017, respectively). In BCLC stage 0-B, all-cause mortality increased with age and increased rapidly around the age of 40 years (non-linear, p < 0.05). In BCLC stages 0-B, HCC-related and non-HCC-related deaths significantly differed between younger and older individuals (p = 0.0019). CONCLUSION: In stage BCLC 0-B, age affects the long-term prognosis of patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09293-x. BioMed Central 2022-02-18 /pmc/articles/PMC8855543/ /pubmed/35180841 http://dx.doi.org/10.1186/s12885-022-09293-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yan, Huiwen Wang, Xinhui Liu, Xiaoli Wang, Peng Yu, Lihua Zhou, Dongdong Yang, Zhiyun The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model |
title | The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model |
title_full | The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model |
title_fullStr | The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model |
title_full_unstemmed | The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model |
title_short | The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model |
title_sort | survival strength of younger patients in bclc stage 0-b of hepatocellular carcinoma: basing on competing risk model |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855543/ https://www.ncbi.nlm.nih.gov/pubmed/35180841 http://dx.doi.org/10.1186/s12885-022-09293-x |
work_keys_str_mv | AT yanhuiwen thesurvivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT wangxinhui thesurvivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT liuxiaoli thesurvivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT wangpeng thesurvivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT yulihua thesurvivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT zhoudongdong thesurvivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT yangzhiyun thesurvivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT yanhuiwen survivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT wangxinhui survivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT liuxiaoli survivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT wangpeng survivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT yulihua survivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT zhoudongdong survivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel AT yangzhiyun survivalstrengthofyoungerpatientsinbclcstage0bofhepatocellularcarcinomabasingoncompetingriskmodel |